News | November 16, 2011

MUSTELA Trial Finds Coronary Thrombectomy Effective in Combination with Primary PCI

November 16, 2011 — Coronary thrombectomy in conjunction with percutaneous coronary intervention improved the rates of ST-segment elevation resolution when compared to a control group but did not show large differences in reduction of infarct size.

Results of the MUSTELA (A Prospective, Randomized Trial of Thrombectomy vs. no Thrombectomy in Patients with ST-Segment Elevation Myocardial Infarction and Thrombus-Rich Lesions) trial were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. TCT was sponsored by the Cardiovascular Research Foundation.

Thrombectomy is the removal of a blood clot, or thrombus. The trial’s purpose was to determine whether coronary thrombectomy as an adjunct to primary percutaneous coronary intervention (PPCI) in patients with high thrombotic burden improves myocardial perfusion and reduces infarct size. Efficacy was assessed by magnetic resonance imaging (MRI).

In this multi-center prospective trial, researchers randomized 208 consecutive patients with ST-elevation myocardial infarction (STEMI), pain-to-balloon-time <12 hours, and angiographic evidence of high thrombotic burden (thrombus grade ?3). Patients were randomized to either standard PPCI (Group A) or PPCI with thrombectomy (Group B) in a 1:1 ratio. The thrombectomy arm was divided between use of rheolytic and aspiration thrombectomy devices.

The primary endpoints were infarct size at three months (assessed with delayed-enhancement MRI) and ST-segment elevation resolution greater than 70 percent at 60 minutes after primary PCI.

ST-segment elevation resolution of greater than 70 percent occurred in 37.3 percent of the control group and 57.4 percent of the thrombectomy group.

Infarct size (IS) was reduced 19.3 percent in the control group and 20.4 percent in the thrombectomy group. A further analysis showed presence of myocardial vascular obstruction (MVO) in the control group together with less dysomogeneus scar (islands of viable myocardium inside the IS.)

Both thrombectomy systems showed to be feasible with a slight advantage for rheolytic thrombectomy.

“There were no coronary complications associated with thrombectomy,” said Anna Sonia Petronio, M.D., the lead investigator of the trial. Petronio is an associate professor and head of the cath lab in the cardiothoracic and vascular department at the University of Pisa in Italy.

For more information: www.crf.org

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init